Forest Laboratories
Executive Summary
Acquires the rights to DuPont Merck's antiviral agent rimantadine for prevention and treatment of influenza A. Financial terms were not disclosed. Pending FDA approval of the rimantadine NDA, which has been at FDA since November 1986, Forest will market the drug under the brandname Flumadine. The NDA stalled at FDA, despite an advisory committee approval recommendation, after a December 1989 New England Journal of Medicine article described rimatadine- resistant influenza.